HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced it has selected ...

HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) ("HYTN" or the "Company") announces that its Board of Directors has approved the spin-out of an internally developed peptide drug ...

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

FDA moves shaping drug development and oversight include new gene therapy guidance, clinical trial transparency efforts, and recent drug approvals.

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...

By Maggie Fick LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely ...

Andrew Pierce is the senior vice president of discovery and development at a company that claims to be “first end-to-end AI biotech,” but he admits he doesn’t know the first thing about artificial ...

The AIRFoundry facility — funded by a six-year, $18 million National Science Foundation grant — brings together researchers ...